GS 9876

Drug Profile

GS 9876

Alternative Names: GS-9876

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Developer Galapagos NV; Gilead Sciences
  • Class Antirheumatics
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Lupus nephritis; Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 06 Oct 2017 Phase-II clinical trials in Lupus nephritis (Combination therapy) in USA (PO) (NCT03285711)
  • 22 Sep 2017 Gilead Sciences plans a phase II trial for Lupus nephritis (Combination therapy) (NCT03285711)
  • 20 Sep 2017 Gilead Sciences completes a phase II trial in Rheumatoid arthritis (Adjunctive treatment) in USA, Bulgaria, Czech Republic, Poland, Georgia, Moldova and Ukraine (NCT02885181)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top